Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Hagens Berman issued a solicitation notice to Aardvark Therapeutics investors regarding a class action lawsuit alleging securities fraud related to the company's IPO and subsequent disclosures. The lawsuit centers on claims that the company misled investors regarding the safety profile of its drug ARD-101, specifically regarding cardiac observations that resulted in an FDA clinical hold.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.